ARC shareholders approve Shell’s proposed purchase of the Canadian natural gas producer for $16.4 billion, according to reports covering the vote. The deal advances Shell’s strategy to expand its North American natural gas portfolio. The transactions bring together Shell’s position in natural gas markets with ARC’s Canadian operations, as Shell seeks additional scale and supply in the region. The reported transaction value is $16.4 billion and reflects the consideration agreed as part of the acquisition arrangement. While the sources focus on shareholder approval and Shell’s stated rationale, details on the timing of closing and any remaining regulatory steps are not provided in the excerpts. The approval indicates that shareholders have endorsed the acquisition at the proposed price, moving the transaction to subsequent procedural stages before it can be completed. Overall, both outlets describe the same core outcome: ARC shareholders greenlight the $16.4 billion deal for Shell to buy the company, with the overarching goal of strengthening Shell’s North American natural gas business.
ARC shareholders approve $16.4 billion Shell acquisition
ARC shareholders approve Shell’s proposed purchase of the Canadian natural gas producer for $16.4 billion, according to reports covering the vote. The deal advances Shell’s strategy to expand its Nort...
- ARC shareholders approve Shell’s acquisition of ARC.
- The deal value is $16.4 billion.
- Shell is buying the Canadian natural gas producer.
- The acquisition is aimed at expanding Shell’s North American natural gas portfolio.
Shell is buying the Canadian natural gas producer as it seeks to expand its North American natural gas portfolio
18 hours agoCDON AB reports 2026 Q2 results in earnings call and investor presentation
CDON AB holds an earnings call and publishes an investor presentation covering its 2026 second-quarter performance. Acro...
Africa focuses on capacity building to shape the continent’s energy future
Several reports highlight that Africa’s energy sector requires more than new capital and technology to progress. They ar...
Septa Pharmaceuticals acquires CeeNU (lomustine) from Bristol Myers Squibb in Canada
Septa Pharmaceuticals Inc. announces it has successfully acquired CeeNU® (lomustine) from Bristol Myers Squibb Canada, w...